Nonalcoholic Steatohepatitis (NASH) – Bullish Market with market size USD 49 Billion by 2027. For more information on DelveInsight’s report please visit :

Image Posted on Updated on



Biosimilar Market in India

Posted on Updated on

Today’s opportunity for Indian companies in biosimilars is not much different from that of the generics industry in 1984. According to Ministry of Commerce and Industry, India’s pharmaceutical export segment has more than doubled from $ 7.8 billion in 2008 to $ 16.5 billion in 2014. With biologic treatments introduced for diseases such as diabetes, cancer, multiple sclerosis, and rheumatoid arthritis, potentially lucrative biosimilar market could emerge as another growth driver of India’s pharmaceutical sector. India has a strong potential to emerge as a key player in the manufacture and marketing of biosimilars.

There are few Indian pharmaceutical companies substantially investing resources towards expanding their biosimilar portfolios. Dr. Reddy’s Laboratories, an Indian multinational pharmaceutical company, is one of the key players in the forefront of the biosimilar segment and has developed Reditux™, the world’s first biosimilar antibody. Biocon Ltd, which received its first approval for insulin glargine in a developed market (Japan) in March this year, is gearing up to submit application for approval in Europe and the US for its four products in FY17.

To increase global reach and market acceptance of their products, Indian companies are setting up manufacturing base overseas. For example, Biocon has reportedly invested $ 200 million on its just commissioned insulin plant in Malaysia. Similarly, Cipla is investing about Rs 600 crore (Rand 1.3 billion) in the new biosimilar manufacturing facility in South Africa, which the company intends to use to serve local as well export markets such as US, Europe and Asia.

Though biosimilars have emerged as important tool to treat cancer and autoimmune diseases, they are only used by about 8 percent of patients worldwide due to the high costs of these drugs. As more companies join the bio-generics race, prices are likely to fall resulting in higher usage. Although India does not have stringent regulations, it has a big potential for biosimilars. Most innovator biotherapeutics are unaffordable to the average patient in India, even though the price in the local market is usually lower than that in Western countries.

Insight by:
Sukhvinder Singh
Associate Analyst
DelveInsight Business Research

DelveInsight’s Indication Active Pharmaceutical Ingredient (API) Reports– 2015

Posted on

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports

Indication-API Insights

DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic area such as Oncology, Cardiovascular disease, and Autoimmune disorders and Infectious disease.

DelveInsight’s Indication API insight report provides global competitive and therapeutic assessment on marketed drugs, API manufacturers, patent expiration and exclusivity. The report gives clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries. These Reports gives complete information on marketed drugs along with Global API Manufacturers and regulatory filings across Europe, US, India and China. It gives information of global Market therapeutics scenario, regulatory information, marketing status and detail of product profiles for marketed products with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical description. The Report also provides Global drug sales forecast up to 2016.

The Reports give opportunities to generic manufacturers and also helps API industry to track closest competitors and prioritizing new drug intermediates to add to the portfolio when drug goes off patent. The Indication API insight report helps to identify the strategic drivers and market opportunities.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on API insight Reports, email at

About us

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Website Link:

DelveInsight’s Marketed and Pipeline Reports Going Viral!

Posted on Updated on

If a market is growing enormously, you need to understand what’s nourishing it


DelveInsight Report

DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights.

Pharm Delve reports are known for its extensive detailed information of the Marketed drugs– Global Market, API Market & Manufacturers across the US, Europe and Asia specifically China and India and Phase III Pipeline drugs information. These reports provide whole list of companies interested in your business. It gives you the most up to date information on drug marketed data, patent data, upcoming API with lots of potential in market, interested Generic Drug Companies, Active Pharmaceutical Ingredient (API) Manufacturers to determine which companies and therapies are emerging leaders while understanding the market needs.

Pharm Insights covers the pipeline reports. Mechanism of Action Reports launched has become the most known and on demand amongst the clients. The report has highlighted all the under development drugs falling under the specific MOA with the comparative analysis at various stages and therapeutics assessment by monotherapy and combination products and molecule type drug information. The reports have covered each and every detail of the drugs while chemical information and company profile are considered thoroughly.

Five worth Reason for Spending on these Reports

  1. Track your closest Competitors
  2. Identifying potential customers
  3. Prioritizing new drug intermediates to add to the portfolio
  4. Uncovering opportunities Globally
  5. Organic as well as Inorganic Growth

Who can buy these Reports?

  • Pharma Companies
  • Drug Development Companies
  • Generic Manufacturing Companies
  • API Manufacturers
  • Institutions/Universities

 Where to buy?

You can buy these reports from the resellers given : Report Buyer, Report Linker, ASD Media, VPG Market Research, Market Publishers, Bharat Book Bureau and Report stack

About DelveInsight

DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.